478 related articles for article (PubMed ID: 33523555)
1. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
Swartz AW; Drappatz J
Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
[TBL] [Abstract][Full Text] [Related]
2. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.
Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI
J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803
[TBL] [Abstract][Full Text] [Related]
3. Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: A meta-analysis.
Yang J; He Z; Li M; Hong T; Ouyang T
J Stroke Cerebrovasc Dis; 2023 Aug; 32(8):107243. PubMed ID: 37413715
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases.
Abdelmessih E; Ahuja T; Wo S; Sango A; Papadopoulos J; Green D; Xiang E
J Thromb Thrombolysis; 2024 Mar; 57(3):418-427. PubMed ID: 38281232
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
8. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review.
Iyengar V; Agrawal S; Chiasakul T; Tehranchi K; Mcnichol M; Carney BJ; Leader A; Zwicker JI; Patell R
J Thromb Haemost; 2024 Feb; 22(2):423-429. PubMed ID: 37866517
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.
Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L
J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
13. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract][Full Text] [Related]
14. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
[TBL] [Abstract][Full Text] [Related]
15. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
[TBL] [Abstract][Full Text] [Related]
16. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.
Leader A; Hamulyák EN; Carney BJ; Avrahami M; Knip JJ; Rozenblatt S; Beenen LFM; Yust-Katz S; Icht O; Coppens M; Raanani P; Middeldorp S; Büller HR; Zwicker JI; Spectre G
Blood Adv; 2020 Dec; 4(24):6291-6297. PubMed ID: 33351124
[TBL] [Abstract][Full Text] [Related]
17. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P; Bilen MA; Gao X; Heng D; Pal S; Narra R; Kilari D; Kaymakcalan MD; McGregor B; Choueiri TK; McKay RR
Clin Genitourin Cancer; 2023 Feb; 21(1):55-62. PubMed ID: 36411184
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis.
Zhou H; Chen TT; Ye LL; Ma JJ; Zhang JH
World J Surg Oncol; 2024 Feb; 22(1):69. PubMed ID: 38403630
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
